Impact of inotuzumab ozogamicin as bridging therapy and tumor burden in CAR-T therapy for B-acute lymphoblastic leukemia

[Introduction:] Inotuzumab ozogamicin is increasingly being used as bridging therapy (BT) prior to chimeric antigen receptor T-cell (CAR-T) in relapsed/refractory B-cell acute lymphoblastic leukemia (R/R ALL), but its impact on CAR-T expansion and clinical outcomes remains controversial.

Detalles Bibliográficos
Autores: Alcalde-Mellado, Patricia, Ruiz-Maldonado, Victoria, Delgado-Serrano, Javier, Sanoja-Flores, Luzalba, Reinoso-Segura, Marta, Pérez-Ortega, Laura, Sierro-Martínez, Belén, García-Guerrero, Estefanía, Pérez de Soto, Concepción, Pérez-Hurtado, José M., González-Campos, José, Pérez-Simón, José A., Molinos-Quintana, A., Caballero-Velázquez, Teresa
Tipo de recurso: artículo
Estado:Versión publicada
Fecha de publicación:2025
País:España
Institución:Consejo Superior de Investigaciones Científicas (CSIC)
Repositorio:DIGITAL.CSIC. Repositorio Institucional del CSIC
OAI Identifier:oai:digital.csic.es:10261/419864
Acceso en línea:http://hdl.handle.net/10261/419864
https://api.elsevier.com/content/abstract/scopus_id/105026364741
Access Level:acceso abierto
Palabra clave:CAR-T
Acute lymphoblastic leukemia
Bridging therapy
Flow cytometry
Inotuzumab ozogamicin
Stem memory T cells
Descripción
Sumario:[Introduction:] Inotuzumab ozogamicin is increasingly being used as bridging therapy (BT) prior to chimeric antigen receptor T-cell (CAR-T) in relapsed/refractory B-cell acute lymphoblastic leukemia (R/R ALL), but its impact on CAR-T expansion and clinical outcomes remains controversial.

Similares en LA Referencia